25 XP   0   0   10

Cyclacel Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Cyclacel together

PenkeI guess you are interested in Cyclacel Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyclacel Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyclacel Pharmaceuticals Inc

I send you an email if I find something interesting about Cyclacel Pharmaceuticals Inc.

Quick analysis of Cyclacel (30 sec.)










What can you expect buying and holding a share of Cyclacel? (30 sec.)

How much money do you get?

How much money do you get?
$0.15
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$0.46
Expected worth in 1 year
$-10.84
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-11.15
Return On Investment
-484.9%

For what price can you sell your share?

Current Price per Share
$2.30
Expected price per share
$1.52 - $3.08
How sure are you?
50%

1. Valuation of Cyclacel (5 min.)




Live pricePrice per Share (EOD)

$2.30

Intrinsic Value Per Share

$-182.54 - $-36.44

Total Value Per Share

$-182.08 - $-35.98

2. Growth of Cyclacel (5 min.)




Is Cyclacel growing?

Current yearPrevious yearGrowGrow %
How rich?$607k$26.4m-$19.1m-261.6%

How much money is Cyclacel making?

Current yearPrevious yearGrowGrow %
Making money-$5.6m-$5.2m-$355.5k-6.3%
Net Profit Margin-14,142.5%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cyclacel (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#852 / 1010

Most Revenue
#628 / 1010

Most Profit
#451 / 1010

Most Efficient
#949 / 1010

What can you expect buying and holding a share of Cyclacel? (5 min.)

Welcome investor! Cyclacel's management wants to use your money to grow the business. In return you get a share of Cyclacel.

What can you expect buying and holding a share of Cyclacel?

First you should know what it really means to hold a share of Cyclacel. And how you can make/lose money.

Speculation

The Price per Share of Cyclacel is $2.2999. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclacel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclacel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.46. Based on the TTM, the Book Value Change Per Share is $-2.83 per quarter. Based on the YOY, the Book Value Change Per Share is $1.99 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.04 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclacel.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-4.00-173.9%-4.24-184.4%-1.74-75.6%-1.74-75.5%-2.38-103.4%
Usd Book Value Change Per Share-2.84-123.5%-2.83-122.9%1.9986.7%-0.56-24.2%-0.52-22.6%
Usd Dividend Per Share0.041.6%0.041.7%0.010.6%0.021.0%0.031.3%
Usd Total Gains Per Share-2.80-121.8%-2.79-121.2%2.0187.3%-0.53-23.2%-0.49-21.3%
Usd Price Per Share2.67-1.05-1.56-2.58-2.43-
Price to Earnings Ratio-0.17--0.06--0.83--1.09--0.68-
Price-to-Total Gains Ratio-0.95--0.53--2.92-0.69--0.13-
Price to Book Ratio5.80-1.51-0.50-0.77-0.47-
Price-to-Total Gains Ratio-0.95--0.53--2.92-0.69--0.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.2999
Number of shares434
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.02
Usd Book Value Change Per Share-2.83-0.56
Usd Total Gains Per Share-2.79-0.53
Gains per Quarter (434 shares)-1,209.97-231.60
Gains per Year (434 shares)-4,839.89-926.41
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
166-4906-485039-966-936
2132-9812-969078-1931-1862
3199-14718-14530118-2897-2788
4265-19624-19370157-3862-3714
5331-24530-24210196-4828-4640
6397-29436-29050235-5794-5566
7463-34342-33890274-6759-6492
8529-39249-38730314-7725-7418
9596-44155-43570353-8690-8344
10662-49061-48410392-9656-9270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.083.00.01.2%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%8.032.00.020.0%17.063.04.020.2%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%70.00.014.083.3%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%8.032.00.020.0%19.062.03.022.6%

Fundamentals of Cyclacel

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 05:41:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyclacel Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyclacel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Net Profit Margin of -17,003.2% means that $-170.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -17,003.2%. The company is making a huge loss. -2
  • The TTM is -14,142.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-17,003.2%TTM-14,142.5%-2,860.7%
TTM-14,142.5%YOY--14,142.5%
TTM-14,142.5%5Y-2,889.9%-11,252.6%
5Y-2,889.9%10Y-1,853.7%-1,036.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17,003.2%-200.1%-16,803.1%
TTM-14,142.5%-216.8%-13,925.7%
YOY--288.3%+288.3%
5Y-2,889.9%-449.1%-2,440.8%
10Y-1,853.7%-605.5%-1,248.2%
1.1.2. Return on Assets

Shows how efficient Cyclacel is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • -59.9% Return on Assets means that Cyclacel generated $-0.60 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -59.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-59.9%TTM-42.1%-17.8%
TTM-42.1%YOY-16.7%-25.4%
TTM-42.1%5Y-17.6%-24.4%
5Y-17.6%10Y-14.7%-2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-59.9%-13.3%-46.6%
TTM-42.1%-12.8%-29.3%
YOY-16.7%-11.7%-5.0%
5Y-17.6%-13.9%-3.7%
10Y-14.7%-15.7%+1.0%
1.1.3. Return on Equity

Shows how efficient Cyclacel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • -868.4% Return on Equity means Cyclacel generated $-8.68 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -868.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -276.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-868.4%TTM-276.2%-592.2%
TTM-276.2%YOY-23.6%-252.6%
TTM-276.2%5Y-66.9%-209.3%
5Y-66.9%10Y-41.2%-25.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-868.4%-16.9%-851.5%
TTM-276.2%-16.1%-260.1%
YOY-23.6%-15.1%-8.5%
5Y-66.9%-19.3%-47.6%
10Y-41.2%-20.2%-21.0%

1.2. Operating Efficiency of Cyclacel Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyclacel is operating .

  • Measures how much profit Cyclacel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • An Operating Margin of -18,580.6% means the company generated $-185.81  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -18,580.6%. The company is operating very inefficient. -2
  • The TTM is -15,732.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-18,580.6%TTM-15,732.8%-2,847.9%
TTM-15,732.8%YOY--15,732.8%
TTM-15,732.8%5Y-3,220.7%-12,512.0%
5Y-3,220.7%10Y-2,107.5%-1,113.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18,580.6%-296.2%-18,284.4%
TTM-15,732.8%-232.5%-15,500.3%
YOY--298.2%+298.2%
5Y-3,220.7%-492.1%-2,728.6%
10Y-2,107.5%-632.4%-1,475.1%
1.2.2. Operating Ratio

Measures how efficient Cyclacel is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 186.81 means that the operating costs are $186.81 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 186.806. The company is inefficient in keeping operating costs low. -1
  • The TTM is 158.488. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ186.806TTM158.488+28.319
TTM158.488YOY-+158.488
TTM158.4885Y32.770+125.718
5Y32.77010Y26.512+6.257
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ186.8063.231+183.575
TTM158.4883.310+155.178
YOY-3.890-3.890
5Y32.7705.739+27.031
10Y26.5127.876+18.636

1.3. Liquidity of Cyclacel Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyclacel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.91 means the company has $0.91 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.912. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.785. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.912TTM1.785-0.873
TTM1.785YOY5.498-3.713
TTM1.7855Y8.320-6.535
5Y8.32010Y6.468+1.852
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9123.890-2.978
TTM1.7854.173-2.388
YOY5.4985.344+0.154
5Y8.3206.126+2.194
10Y6.4686.448+0.020
1.3.2. Quick Ratio

Measures if Cyclacel is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Quick Ratio of 0.77 means the company can pay off $0.77 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.773. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.591. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.773TTM1.591-0.817
TTM1.591YOY5.335-3.745
TTM1.5915Y8.021-6.431
5Y8.02110Y6.170+1.851
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7733.514-2.741
TTM1.5913.998-2.407
YOY5.3355.380-0.045
5Y8.0216.105+1.916
10Y6.1706.404-0.234

1.4. Solvency of Cyclacel Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyclacel assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyclacel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.93 means that Cyclacel assets are financed with 93.1% credit (debt) and the remaining percentage (100% - 93.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.931. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.583. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.931TTM0.583+0.348
TTM0.583YOY0.221+0.362
TTM0.5835Y0.242+0.341
5Y0.24210Y0.235+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9310.339+0.592
TTM0.5830.336+0.247
YOY0.2210.271-0.050
5Y0.2420.366-0.124
10Y0.2350.389-0.154
1.4.2. Debt to Equity Ratio

Measures if Cyclacel is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Debt to Equity ratio of 1,350.6% means that company has $13.51 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 13.506. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.144. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ13.506TTM4.144+9.362
TTM4.144YOY0.324+3.820
TTM4.1445Y0.991+3.153
5Y0.99110Y0.645+0.346
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5060.388+13.118
TTM4.1440.402+3.742
YOY0.3240.335-0.011
5Y0.9910.426+0.565
10Y0.6450.461+0.184

2. Market Valuation of Cyclacel Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cyclacel generates.

  • Above 15 is considered overpriced but always compare Cyclacel to the Biotechnology industry mean.
  • A PE ratio of -0.17 means the investor is paying $-0.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is -0.144. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.167. Based on the earnings, the company is expensive. -2
  • The TTM is -0.064. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.144MRQ-0.167+0.023
MRQ-0.167TTM-0.064-0.103
TTM-0.064YOY-0.832+0.768
TTM-0.0645Y-1.092+1.028
5Y-1.09210Y-0.680-0.412
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.144-2.264+2.120
MRQ-0.167-2.629+2.462
TTM-0.064-2.680+2.616
YOY-0.832-4.145+3.313
5Y-1.092-6.257+5.165
10Y-0.680-6.254+5.574
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is -0.194. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.225. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.108. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.194MRQ-0.225+0.031
MRQ-0.225TTM-0.108-0.118
TTM-0.108YOY-0.810+0.702
TTM-0.1085Y-1.373+1.265
5Y-1.37310Y-0.994-0.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.194-2.973+2.779
MRQ-0.225-3.333+3.108
TTM-0.108-3.553+3.445
YOY-0.810-5.605+4.795
5Y-1.373-8.376+7.003
10Y-0.994-8.865+7.871
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyclacel is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.80 means the investor is paying $5.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is 4.995. Based on the equity, the company is fair priced.
  • The MRQ is 5.799. Based on the equity, the company is overpriced. -1
  • The TTM is 1.510. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.995MRQ5.799-0.804
MRQ5.799TTM1.510+4.289
TTM1.510YOY0.502+1.007
TTM1.5105Y0.770+0.739
5Y0.77010Y0.474+0.297
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.9951.896+3.099
MRQ5.7992.115+3.684
TTM1.5102.093-0.583
YOY0.5022.884-2.382
5Y0.7703.542-2.772
10Y0.4743.916-3.442
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyclacel Pharmaceuticals Inc.

3.1. Institutions holding Cyclacel Pharmaceuticals Inc

Institutions are holding 15.367% of the shares of Cyclacel Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Point72 Asset Management, L.P.1.16320.000223000000
2023-12-31Altium Capital Management, LP2.88120.068837982379820
2023-09-30Citadel Advisors Llc0.155503074519157165.3176
2023-09-30Schonfeld Strategic Advisors LLC0.14360.000128400-636366-95.7278
2023-12-31Acadian Asset Management LLC1.83750.00022422310.0041
2023-12-31Renaissance Technologies Corp1.09520.000114438207316.7651
2023-12-31Mcilrath & Eck, LLC0.06310.0004832-1-0.12
2023-12-31Tower Research Capital LLC0.06120807568237.6569
2023-12-31Advisor Group Holdings, Inc.0.00960126-484-79.3443
2023-12-31Morgan Stanley - Brokerage Accounts0.006108000
2023-12-31Wells Fargo & Co0.00303900
2023-12-31BlackRock Inc0.0019025-288-92.0128
2023-12-31SignatureFD, LLC0.001502000
2023-09-30SIMPLEX TRADING, LLC0.000101700
2023-12-31HARBOUR INVESTMENTS, INC.0.001013130
2023-12-31Qube Research & Technologies0.00020300
2023-12-31State Street Corporation000-701-100
2023-09-30Susquehanna International Group, LLP000-12312-100
2023-12-31Northern Trust Corp000-997-100
2023-09-30Bridgeway Capital Management, LLC000-64068-100
Total 7.42390.0698367750-655423-178.2%

3.2. Funds holding Cyclacel Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.43970579600
2024-02-29Fidelity Extended Market Index0.32530428800
2024-02-29Fidelity Nasdaq Composite Index0.0538070900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0434057200
2024-02-29Fidelity Series Total Market Index0.043056700
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0349046010.2179
2023-09-30BlackRock Extended Mkt Composite0.002038900
2023-12-31Northern Trust Extended Eq Market Idx0.0289038100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0289038100
2024-02-29Spartan Total Market Index Pool E0.0147019400
2023-12-31Northern Trust Wilshire 50000.003304400
2023-12-31NT US Market Cap Idx Fd - L0.003304400
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001401800
Total 1.0226013843+1+0.0%

3.3. Insider Transactions

Insiders are holding 6.328% of the shares of Cyclacel Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-21Paul McbarronBUY18863.31
2023-12-21Spiro George RombotisBUY60703.31

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cyclacel Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.840-2.8260%1.995-242%-0.556-80%-0.520-82%
Book Value Per Share--0.4605.543-92%5.061-91%6.667-93%10.792-96%
Current Ratio--0.9121.785-49%5.498-83%8.320-89%6.468-86%
Debt To Asset Ratio--0.9310.583+60%0.221+322%0.242+284%0.235+295%
Debt To Equity Ratio--13.5064.144+226%0.324+4064%0.991+1262%0.645+1992%
Dividend Per Share--0.0380.0380%0.013+192%0.023+68%0.030+25%
Eps---3.998-4.241+6%-1.739-57%-1.737-57%-2.377-41%
Free Cash Flow Per Share---2.966-3.057+3%-1.339-55%-1.508-49%-1.850-38%
Free Cash Flow To Equity Per Share---2.208-2.896+31%-1.264-43%-0.817-63%-0.655-70%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---36.437--------
Intrinsic Value_10Y_min---182.541--------
Intrinsic Value_1Y_max---6.147--------
Intrinsic Value_1Y_min---9.311--------
Intrinsic Value_3Y_max---16.567--------
Intrinsic Value_3Y_min---35.920--------
Intrinsic Value_5Y_max---24.694--------
Intrinsic Value_5Y_min---71.031--------
Market Cap3031866.174-16%3519754.2001378998.830+155%15071187.158-77%16799088.535-79%9904186.457-64%
Net Profit Margin---170.032-141.425-17%--100%-28.899-83%-18.537-89%
Operating Margin---185.806-157.328-15%--100%-32.207-83%-21.075-89%
Operating Ratio--186.806158.488+18%-+100%32.770+470%26.512+605%
Pb Ratio4.995-16%5.7991.510+284%0.502+1055%0.770+653%0.474+1124%
Pe Ratio-0.144+14%-0.167-0.064-62%-0.832+398%-1.092+554%-0.680+307%
Price Per Share2.300-16%2.6701.046+155%1.564+71%2.583+3%2.433+10%
Price To Free Cash Flow Ratio-0.194+14%-0.225-0.108-52%-0.810+260%-1.373+510%-0.994+342%
Price To Total Gains Ratio-0.821+14%-0.953-0.530-44%-2.921+207%0.689-238%-0.126-87%
Quick Ratio--0.7731.591-51%5.335-86%8.021-90%6.170-87%
Return On Assets---0.599-0.421-30%-0.167-72%-0.176-71%-0.147-75%
Return On Equity---8.684-2.762-68%-0.236-97%-0.669-92%-0.412-95%
Total Gains Per Share---2.802-2.788-1%2.008-240%-0.534-81%-0.490-83%
Usd Book Value--607000.0007307500.000-92%26421750.000-98%22915500.000-97%21290275.000-97%
Usd Book Value Change Per Share---2.840-2.8260%1.995-242%-0.556-80%-0.520-82%
Usd Book Value Per Share--0.4605.543-92%5.061-91%6.667-93%10.792-96%
Usd Dividend Per Share--0.0380.0380%0.013+192%0.023+68%0.030+25%
Usd Eps---3.998-4.241+6%-1.739-57%-1.737-57%-2.377-41%
Usd Free Cash Flow---3910000.000-4029500.000+3%-5208502.498+33%-3650300.500-7%-3270650.250-16%
Usd Free Cash Flow Per Share---2.966-3.057+3%-1.339-55%-1.508-49%-1.850-38%
Usd Free Cash Flow To Equity Per Share---2.208-2.896+31%-1.264-43%-0.817-63%-0.655-70%
Usd Market Cap3031866.174-16%3519754.2001378998.830+155%15071187.158-77%16799088.535-79%9904186.457-64%
Usd Price Per Share2.300-16%2.6701.046+155%1.564+71%2.583+3%2.433+10%
Usd Profit---5271000.000-5655000.000+7%-5299500.000+1%-3948950.000-25%-3481400.000-34%
Usd Revenue--31000.000105000.000-70%-+100%28500.000+9%138025.000-78%
Usd Total Gains Per Share---2.802-2.788-1%2.008-240%-0.534-81%-0.490-83%
 EOD+3 -5MRQTTM+13 -22YOY+7 -285Y+4 -3110Y+3 -33

4.2. Fundamental Score

Let's check the fundamental score of Cyclacel Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.144
Price to Book Ratio (EOD)Between0-14.995
Net Profit Margin (MRQ)Greater than0-170.032
Operating Margin (MRQ)Greater than0-185.806
Quick Ratio (MRQ)Greater than10.773
Current Ratio (MRQ)Greater than10.912
Debt to Asset Ratio (MRQ)Less than10.931
Debt to Equity Ratio (MRQ)Less than113.506
Return on Equity (MRQ)Greater than0.15-8.684
Return on Assets (MRQ)Greater than0.05-0.599
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Cyclacel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.637
Ma 20Greater thanMa 501.968
Ma 50Greater thanMa 1002.310
Ma 100Greater thanMa 2002.618
OpenGreater thanClose1.860
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Working Capital  17,019-5,38311,636-3,0888,548-5,5293,019-3,736-717



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets8,805
Total Liabilities8,198
Total Stockholder Equity607
 As reported
Total Liabilities 8,198
Total Stockholder Equity+ 607
Total Assets = 8,805

Assets

Total Assets8,805
Total Current Assets7,444
Long-term Assets1,361
Total Current Assets
Cash And Cash Equivalents 3,378
Net Receivables 2,933
Other Current Assets 1,133
Total Current Assets  (as reported)7,444
Total Current Assets  (calculated)7,444
+/-0
Long-term Assets
Property Plant Equipment 102
Long-term Assets Other 1,259
Long-term Assets  (as reported)1,361
Long-term Assets  (calculated)1,361
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,161
Long-term Liabilities37
Total Stockholder Equity607
Total Current Liabilities
Accounts payable 3,543
Other Current Liabilities 4,618
Total Current Liabilities  (as reported)8,161
Total Current Liabilities  (calculated)8,161
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt37
Long-term Liabilities  (as reported)37
Long-term Liabilities  (calculated)37
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -428,282
Accumulated Other Comprehensive Income -908
Other Stockholders Equity 429,796
Total Stockholder Equity (as reported)607
Total Stockholder Equity (calculated)607
+/-0
Other
Capital Stock1
Cash and Short Term Investments 3,378
Common Stock Shares Outstanding 854
Liabilities and Stockholders Equity 8,805
Net Debt -3,341
Net Invested Capital 607
Net Working Capital -717
Property Plant and Equipment Gross 522
Short Long Term Debt Total 37



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-31
> Total Assets 
0
0
0
18,498
45,013
39,860
35,006
55,603
48,577
41,308
30,195
21,445
38,136
72,667
67,520
63,276
90,246
85,539
80,440
75,912
66,121
57,218
41,625
30,957
25,167
19,460
17,542
14,466
26,776
22,309
20,391
31,459
27,197
22,695
28,946
25,998
25,338
21,802
20,526
19,354
19,354
37,510
37,989
35,520
33,785
37,610
31,630
29,387
35,357
30,788
27,049
24,764
21,461
18,877
22,652
19,662
17,073
16,083
27,851
26,003
24,777
22,730
20,707
19,823
21,510
19,464
17,077
15,308
12,987
29,171
27,213
36,802
51,817
46,334
44,999
42,587
39,629
35,346
31,021
27,501
22,060
16,442
12,432
8,805
8,80512,43216,44222,06027,50131,02135,34639,62942,58744,99946,33451,81736,80227,21329,17112,98715,30817,07719,46421,51019,82320,70722,73024,77726,00327,85116,08317,07319,66222,65218,87721,46124,76427,04930,78835,35729,38731,63037,61033,78535,52037,98937,51019,35419,35420,52621,80225,33825,99828,94622,69527,19731,45920,39122,30926,77614,46617,54219,46025,16730,95741,62557,21866,12175,91280,44085,53990,24663,27667,52072,66738,13621,44530,19541,30848,57755,60335,00639,86045,01318,498000
   > Total Current Assets 
0
0
0
14,059
41,240
35,007
28,243
48,339
40,996
33,747
27,369
20,922
34,003
67,948
62,957
58,165
85,231
80,246
75,166
63,777
54,308
45,814
37,309
29,014
23,431
17,967
16,225
13,369
25,865
21,507
19,683
31,051
26,866
22,449
28,781
25,831
25,172
21,653
19,953
18,872
18,872
37,155
37,719
35,173
33,452
37,281
31,176
29,000
35,024
30,479
26,794
24,566
21,310
18,768
22,579
19,617
17,034
16,051
27,817
25,974
24,732
22,687
20,669
19,787
20,124
18,150
15,836
14,017
11,811
27,933
25,934
35,469
50,463
46,203
43,375
40,942
36,577
32,077
27,915
24,411
18,974
15,294
11,048
7,444
7,44411,04815,29418,97424,41127,91532,07736,57740,94243,37546,20350,46335,46925,93427,93311,81114,01715,83618,15020,12419,78720,66922,68724,73225,97427,81716,05117,03419,61722,57918,76821,31024,56626,79430,47935,02429,00031,17637,28133,45235,17337,71937,15518,87218,87219,95321,65325,17225,83128,78122,44926,86631,05119,68321,50725,86513,36916,22517,96723,43129,01437,30945,81454,30863,77775,16680,24685,23158,16562,95767,94834,00320,92227,36933,74740,99648,33928,24335,00741,24014,059000
       Cash And Cash Equivalents 
0
0
0
2,241
30,498
8,802
3,758
13,897
4,362
10,953
14,020
13,599
23,707
63,101
49,787
44,238
75,215
43,842
31,113
30,987
30,424
31,681
26,723
24,220
20,442
15,864
14,433
11,493
24,200
19,543
18,482
29,495
25,350
20,614
27,675
24,449
23,640
19,964
17,837
16,412
16,412
33,668
34,487
31,146
28,154
33,584
26,707
24,189
29,363
26,902
22,728
20,440
17,115
15,931
18,029
16,520
12,729
13,591
26,025
23,910
21,725
19,824
18,973
17,504
17,934
15,159
12,967
11,885
8,923
25,342
23,130
33,406
47,777
43,639
40,219
36,559
29,639
29,077
23,706
18,345
11,435
10,164
5,944
3,378
3,3785,94410,16411,43518,34523,70629,07729,63936,55940,21943,63947,77733,40623,13025,3428,92311,88512,96715,15917,93417,50418,97319,82421,72523,91026,02513,59112,72916,52018,02915,93117,11520,44022,72826,90229,36324,18926,70733,58428,15431,14634,48733,66816,41216,41217,83719,96423,64024,44927,67520,61425,35029,49518,48219,54324,20011,49314,43315,86420,44224,22026,72331,68130,42430,98731,11343,84275,21544,23849,78763,10123,70713,59914,02010,9534,36213,8973,7588,80230,4982,241000
       Short-term Investments 
0
0
0
11,299
8,821
24,928
23,478
33,421
35,181
21,395
12,702
6,930
6,918
1,886
9,951
9,764
5,536
30,814
37,430
27,766
18,558
8,290
6,998
1,502
1,502
0
0
0
0
0
0
0
0
0
0
19,894
0
0
0
0
0
0
0
0
0
0
0
132
0
0
0
132
0
0
0
132
0
0
0
132
0
0
0
66
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000660001320001320001320001320000000000019,89400000000001,5021,5026,9988,29018,55827,76637,43030,8145,5369,7649,9511,8866,9186,93012,70221,39535,18133,42123,47824,9288,82111,299000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,484
4,480
0
0
2,467
3,146
3,277
1,644
0
0
0
0
0
0
0
0
0
0
0
0
0
0
887
0
0
1,651
0
0
0
0
1,954
0
3,460
4,505
2,125
0
3,026
3,026
1,505
2,007
2,057
3,331
1,048
1,221
1,488
1,278
1,693
816
1,504
1,441
1,710
1,929
1,326
1,525
1,805
2,166
1,313
2,010
1,586
2,514
3,727
4,732
2,000
4,039
5,640
6,944
2,944
3,219
2,933
2,9333,2192,9446,9445,6404,0392,0004,7323,7272,5141,5862,0101,3132,1661,8051,5251,3261,9291,7101,4411,5048161,6931,2781,4881,2211,0483,3312,0572,0071,5053,0263,02602,1254,5053,46001,95400001,65100887000000000000001,6443,2773,1462,467004,4802,484000000000000000
       Other Current Assets 
0
0
0
519
1,921
1,277
1,007
1,021
1,453
1,399
647
393
3,378
2,961
3,219
308
4,480
5,590
6,623
603
212
178
139
2,784
2,529
1,797
1,652
1,731
1,558
1,925
1,057
1,382
1,401
1,688
941
1,200
1,423
266
917
1,427
2,460
817
792
639
580
325
4,469
278
196
237
100
132
75
20
1,669
41
269
332
206
81
684
172
82
170
72
236
119
2,132
1,070
104
140
2,063
2,686
142
3,156
4,383
1,539
79
170
6,066
595
2,186
5,104
1,133
1,1335,1042,1865956,066170791,5394,3833,1561422,6862,0631401041,0702,132119236721708217268481206332269411,66920751321002371962784,4693255806397928172,4601,4279172661,4231,2009411,6881,4011,3821,0571,9251,5581,7311,6521,7972,5292,7841391782126036,6235,5904,4803083,2192,9613,3783936471,3991,4531,0211,0071,2771,921519000
   > Long-term Assets 
0
0
0
4,439
3,773
4,853
6,763
7,264
7,581
7,561
2,826
523
4,133
4,719
4,563
5,111
5,015
5,293
5,274
12,135
11,813
11,404
4,316
1,943
1,736
1,493
1,317
1,097
911
802
708
408
331
246
165
167
166
149
573
0
482
355
270
347
333
329
454
387
333
309
255
198
151
109
73
45
39
32
34
29
45
43
38
36
1,386
1,314
1,241
1,291
1,176
1,238
1,279
1,333
1,354
131
1,624
1,645
3,052
3,269
3,106
3,090
3,086
1,148
1,384
1,361
1,3611,3841,1483,0863,0903,1063,2693,0521,6451,6241311,3541,3331,2791,2381,1761,2911,2411,3141,3863638434529343239457310915119825530933338745432933334727035548205731491661671652463314087088029111,0971,3171,4931,7361,9434,31611,40411,81312,1355,2745,2935,0155,1114,5634,7194,1335232,8267,5617,5817,2646,7634,8533,7734,439000
       Property Plant Equipment 
0
0
0
2,767
2,916
3,905
5,712
6,208
6,496
6,420
1,877
176
1,950
1,711
1,555
2,121
2,025
2,303
2,292
3,016
2,946
2,782
2,288
1,748
1,540
1,297
1,121
901
715
606
512
408
331
246
165
167
166
149
140
129
129
169
174
275
285
305
454
387
333
309
255
198
151
109
73
45
39
32
34
29
45
43
38
36
1,386
1,314
1,241
1,291
1,176
1,238
1,279
1,333
1,354
131
115
94
72
3,269
190
174
170
148
125
102
1021251481701741903,26972941151311,3541,3331,2791,2381,1761,2911,2411,3141,386363843452934323945731091511982553093333874543052852751741691291291401491661671652463314085126067159011,1211,2971,5401,7482,2882,7822,9463,0162,2922,3032,0252,1211,5551,7111,9501761,8776,4206,4966,2085,7123,9052,9162,767000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
1,924
2,749
2,749
2,749
2,749
2,749
2,749
4,618
4,602
4,593
1,832
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000001,8324,5934,6024,6182,7492,7492,7492,7492,7492,7491,924000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
2,749
2,749
2,749
2,749
2,749
2,749
2,749
4,305
4,069
3,833
1,832
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000001,8323,8334,0694,3052,7492,7492,7492,7492,7492,7492,749000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
3,008
3,008
3,008
2,990
2,990
2,990
2,982
9,119
8,867
8,622
2,028
195
196
196
196
196
196
196
196
0
0
0
0
0
0
0
433
353
272
186
96
72
48
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1,509
1,551
2,980
3,060
2,916
2,916
0
1,000
0
0
001,00002,9162,9163,0602,9801,5511,50900100000000000000000000000002448729618627235343300000001961961961961961961961952,0288,6228,8679,1192,9822,9902,9902,9903,0083,0083,008000000000000
> Total Liabilities 
0
0
0
83,338
6,397
6,763
8,123
11,483
11,430
10,009
11,999
6,842
12,744
8,421
8,184
9,357
14,100
12,709
11,865
17,943
14,184
13,810
11,852
10,315
9,966
11,212
9,595
9,822
9,511
8,155
7,965
6,535
6,813
6,040
5,935
6,498
6,802
6,746
7,297
9,335
9,335
6,579
8,978
7,497
8,810
8,021
6,987
7,699
8,328
6,688
5,449
5,929
5,562
5,715
5,711
5,389
4,255
4,447
4,393
4,237
4,382
4,106
4,109
4,551
3,955
3,733
3,225
3,611
2,596
2,593
2,775
3,543
3,768
3,118
3,635
5,324
6,219
5,139
4,460
11,992
7,418
6,812
8,081
8,198
8,1988,0816,8127,41811,9924,4605,1396,2195,3243,6353,1183,7683,5432,7752,5932,5963,6113,2253,7333,9554,5514,1094,1064,3824,2374,3934,4474,2555,3895,7115,7155,5625,9295,4496,6888,3287,6996,9878,0218,8107,4978,9786,5799,3359,3357,2976,7466,8026,4985,9356,0406,8136,5357,9658,1559,5119,8229,59511,2129,96610,31511,85213,81014,18417,94311,86512,70914,1009,3578,1848,42112,7446,84211,99910,00911,43011,4838,1236,7636,39783,338000
   > Total Current Liabilities 
0
0
0
14,712
4,671
4,169
4,590
7,412
7,507
5,921
8,390
5,219
10,951
6,873
6,511
7,921
6,579
11,652
10,901
14,712
11,181
11,615
9,875
8,627
8,549
10,686
9,328
9,822
9,511
8,155
7,965
6,535
6,813
6,040
5,935
6,498
6,802
6,746
7,297
9,335
9,335
6,579
8,978
7,497
8,810
7,783
6,766
7,493
8,136
6,490
5,263
5,753
5,396
5,565
5,570
5,259
4,128
4,319
4,265
4,113
4,258
3,994
4,003
4,451
2,487
2,500
2,071
2,420
1,523
1,512
1,712
2,486
2,772
3,118
3,591
5,294
6,204
5,026
4,353
7,392
7,338
6,746
8,029
8,161
8,1618,0296,7467,3387,3924,3535,0266,2045,2943,5913,1182,7722,4861,7121,5121,5232,4202,0712,5002,4874,4514,0033,9944,2584,1134,2654,3194,1285,2595,5705,5655,3965,7535,2636,4908,1367,4936,7667,7838,8107,4978,9786,5799,3359,3357,2976,7466,8026,4985,9356,0406,8136,5357,9658,1559,5119,8229,32810,6868,5498,6279,87511,61511,18114,71210,90111,6526,5797,9216,5116,87310,9515,2198,3905,9217,5077,4124,5904,1694,67114,712000
       Short-term Debt 
0
0
0
11,652
932
974
1,331
1,556
1,587
1,739
2,987
0
252
218
156
89
19
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
19
0
0
0
0
0
0
0
0
0
0
0
000000000001919000000000000000000000000000000000000000000000000000000198915621825202,9871,7391,5871,5561,33197493211,652000
       Accounts payable 
0
0
0
954
688
2,045
2,162
1,707
1,205
633
882
1,202
3,152
1,908
1,505
2,175
2,076
1,985
2,004
4,958
3,439
2,130
1,301
754
1,812
1,440
1,463
1,709
1,782
1,550
1,340
1,723
947
1,104
1,101
1,763
1,116
1,544
1,642
2,259
2,259
2,437
2,352
2,545
4,719
4,543
2,201
2,792
4,007
2,609
1,616
1,940
1,582
1,898
1,979
2,497
1,652
2,038
1,973
1,558
1,949
1,675
1,411
2,719
1,284
1,106
887
890
250
342
455
514
871
1,197
1,515
2,117
2,850
2,205
983
2,561
2,509
2,169
1,571
3,543
3,5431,5712,1692,5092,5619832,2052,8502,1171,5151,1978715144553422508908871,1061,2842,7191,4111,6751,9491,5581,9732,0381,6522,4971,9791,8981,5821,9401,6162,6094,0072,7922,2014,5434,7192,5452,3522,4372,2592,2591,6421,5441,1161,7631,1011,1049471,7231,3401,5501,7821,7091,4631,4401,8127541,3012,1303,4394,9582,0041,9852,0762,1751,5051,9083,1521,2028826331,2051,7072,1622,045688954000
       Other Current Liabilities 
0
0
0
845
2,206
1,103
1,050
4,102
4,668
3,502
4,474
4,017
3,990
2,013
1,667
1,425
1,040
9,667
8,897
9,754
7,742
9,485
8,574
7,873
6,737
9,246
7,865
8,113
7,729
6,605
6,625
4,812
5,866
4,936
4,834
4,735
5,686
5,202
5,655
7,076
7,076
4,142
6,626
4,952
4,091
3,240
4,565
4,701
4,129
3,881
3,647
3,813
3,814
3,667
3,591
2,762
2,476
2,281
2,292
2,555
2,309
2,319
2,592
1,732
1,203
1,394
1,184
1,530
1,273
1,170
1,257
1,972
1,901
1,921
2,076
3,177
3,354
2,821
3,370
4,831
4,829
4,577
6,458
4,618
4,6186,4584,5774,8294,8313,3702,8213,3543,1772,0761,9211,9011,9721,2571,1701,2731,5301,1841,3941,2031,7322,5922,3192,3092,5552,2922,2812,4762,7623,5913,6673,8143,8133,6473,8814,1294,7014,5653,2404,0914,9526,6264,1427,0767,0765,6555,2025,6864,7354,8344,9365,8664,8126,6256,6057,7298,1137,8659,2466,7377,8738,5749,4857,7429,7548,8979,6671,0401,4251,6672,0133,9904,0174,4743,5024,6684,1021,0501,1032,206845000
   > Long-term Liabilities 
0
0
0
68,626
1,726
2,594
3,533
4,071
3,923
4,088
3,609
1,623
1,793
1,548
1,673
1,436
7,521
1,057
964
3,231
3,003
2,195
1,977
1,688
1,417
526
267
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
238
221
206
192
198
186
176
166
150
141
130
127
128
128
124
124
112
106
100
1,468
1,233
1,154
1,191
1,073
1,081
1,063
1,057
996
0
44
30
15
113
107
4,600
80
66
52
37
375266804,60010711315304409961,0571,0631,0811,0731,1911,1541,2331,4681001061121241241281281271301411501661761861981922062212380000000000000000002675261,4171,6881,9772,1953,0033,2319641,0577,5211,4361,6731,5481,7931,6233,6094,0883,9234,0713,5332,5941,72668,626000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
1,777
1,548
1,673
1,436
7,521
1,057
964
3,231
3,003
2,193
1,977
1,688
1,417
526
267
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
238
221
206
192
198
186
176
166
150
141
130
127
128
128
124
124
112
106
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,494
4,494
0
4,494
0
0
004,49404,4944,494000000000000001001061121241241281281271301411501661761861981922062212380000000000000000002675261,4171,6881,9772,1933,0033,2319641,0577,5211,4361,6731,5481,777000000000000
> Total Stockholder Equity
0
0
0
-64,840
38,616
33,097
26,883
44,120
37,147
31,299
18,196
14,603
25,392
64,246
59,336
53,919
76,146
72,830
68,575
57,969
51,937
43,408
29,773
20,642
15,201
8,248
7,947
4,644
17,265
14,154
12,426
24,924
20,384
16,655
23,011
19,500
18,536
15,056
13,229
10,019
10,019
30,931
29,011
28,023
24,975
29,589
24,643
21,688
27,029
24,100
21,600
18,835
15,899
13,162
16,941
14,273
12,818
11,636
23,458
21,766
20,395
18,624
16,598
15,272
17,555
15,731
13,852
11,697
10,391
26,578
24,438
33,259
48,049
43,216
41,364
37,263
33,410
30,207
26,561
15,509
14,642
9,630
4,351
607
6074,3519,63014,64215,50926,56130,20733,41037,26341,36443,21648,04933,25924,43826,57810,39111,69713,85215,73117,55515,27216,59818,62420,39521,76623,45811,63612,81814,27316,94113,16215,89918,83521,60024,10027,02921,68824,64329,58924,97528,02329,01130,93110,01910,01913,22915,05618,53619,50023,01116,65520,38424,92412,42614,15417,2654,6447,9478,24815,20120,64229,77343,40851,93757,96968,57572,83076,14653,91959,33664,24625,39214,60318,19631,29937,14744,12026,88333,09738,616-64,840000
   Common Stock
0
0
0
2
15
15
15
19
20
19
19
19
10
16
16
16
20
20
20
20
20
20
20
20
20
20
24
26
35
37
37
47
47
47
55
54
59
59
8
9
9
17
18
19
20
23
23
23
34
34
34
35
35
3
4
4
4
4
12
12
12
12
12
12
17
17
17
17
1
5
5
6
9
9
10
10
10
11
4,503
4,503
4,503
4,503
12
1
1124,5034,5034,5034,503111010109965511717171712121212121244443353534343423232320191817998595954554747473737352624202020202020202020201616161019191920191515152000
   Retained Earnings Total Equity0000000000-374,677-369,550-366,072-363,269-361,013-358,847-357,600-355,323-353,422-351,639-349,797-347,778-345,710-343,857-342,509-340,635-338,780-336,594-335,039-332,200-329,254-326,289-323,159-319,785-317,076-313,7290-304,018-299,111-294,299-289,43000000000-253,406-249,961000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-2,779
-3,004
-2,464
-1,856
-1,426
-1,096
-739
-352
-193
-2,861
-2,458
-2,367
-2,537
-2,571
-2,928
-3,286
-2,630
-2,653
-2,726
1,337
-42
71
118
5
20
52
42
-30
31
8
39
49
57
65
78
51
-7,582
48
-5
-172
-109
-101
-97
-305
-480
-691
-388
-540
-596
-662
-737
-760
-743
-748
-736
-762
-794
-846
-801
-796
-760
-781
-808
-913
-819
-946
-934
-881
-746
-730
-658
-753
-748
-823
-1,276
-1,746
-1,316
-1,224
-1,097
-1,168
-908
-908-1,168-1,097-1,224-1,316-1,746-1,276-823-748-753-658-730-746-881-934-946-819-913-808-781-760-796-801-846-794-762-736-748-743-760-737-662-596-540-388-691-480-305-97-101-109-172-548-7,582517865574939831-30425220511871-421,337-2,726-2,653-2,630-3,286-2,928-2,571-2,537-2,367-2,458-2,861-193-352-739-1,096-1,426-1,856-2,464-3,004-2,779000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
266,529
276,312
0
0
0
0
0
0
0
0
317,543
319,355
328,774
328,943
0
341,415
341,530
341,891
342,555
342,815
343,150
349,897
350,051
350,156
351,148
364,843
365,057
365,086
365,123
365,160
365,817
369,958
369,944
370,071
370,126
370,183
388,520
388,583
400,071
418,320
418,542
0
0
0
0
0
0
0
0
0
0
0000000000418,542418,320400,071388,583388,520370,183370,126370,071369,944369,958365,817365,160365,123365,086365,057364,843351,148350,156350,051349,897343,150342,815342,555341,891341,530341,4150328,943328,774319,355317,54300000000276,312266,529000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
24,532
146,484
146,511
146,519
171,708
171,696
171,386
170,540
170,374
148,608
193,995
194,426
194,714
221,861
222,497
222,815
222,906
223,149
223,237
223,186
223,377
222,886
222,932
225,864
226,881
244,991
248,314
250,466
266,666
266,737
266,529
276,312
276,452
278,430
278,514
278,655
0
280,211
311,125
315,036
317,543
319,355
328,774
328,943
330,962
341,415
341,530
341,891
342,555
342,815
343,150
349,897
350,051
350,156
351,148
364,843
365,057
365,086
365,123
365,160
365,817
369,958
369,944
370,071
370,126
370,183
388,520
388,583
400,071
418,320
418,542
421,771
422,960
423,290
425,114
422,542
413,985
418,830
424
428,464
429,796
429,796428,464424418,830413,985422,542425,114423,290422,960421,771418,542418,320400,071388,583388,520370,183370,126370,071369,944369,958365,817365,160365,123365,086365,057364,843351,148350,156350,051349,897343,150342,815342,555341,891341,530341,415330,962328,943328,774319,355317,543315,036311,125280,2110278,655278,514278,430276,452276,312266,529266,737266,666250,466248,314244,991226,881225,864222,932222,886223,377223,186223,237223,149222,906222,815222,497221,861194,714194,426193,995148,608170,374170,540171,386171,696171,708146,519146,511146,48424,532000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue420
Cost of Revenue-31
Gross Profit389389
 
Operating Income (+$)
Gross Profit389
Operating Expense-30,688
Operating Income-30,299-30,299
 
Operating Expense (+$)
Research Development23,970
Selling General Administrative6,718
Selling And Marketing Expenses0
Operating Expense30,68830,688
 
Net Interest Income (+$)
Interest Income365
Interest Expense-0
Other Finance Cost-0
Net Interest Income365
 
Pretax Income (+$)
Operating Income-30,299
Net Interest Income365
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-30,397-30,201
EBIT - interestExpense = -30,299
-30,397
-22,555
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-30,299-30,397
Earnings Before Interest and Taxes (EBITDA)-30,268
 
After tax Income (+$)
Income Before Tax-30,397
Tax Provision--4,155
Net Income From Continuing Ops-24,703-26,242
Net Income-22,555
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses30,719
Total Other Income/Expenses Net-98-365
 

Technical Analysis of Cyclacel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyclacel. The general trend of Cyclacel is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyclacel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyclacel Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.3001 < 3.02 < 3.08.

The bearish price targets are: 2.2311 > 1.52.

Tweet this
Cyclacel Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyclacel Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyclacel Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyclacel Pharmaceuticals Inc. The current macd is -0.10714971.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclacel price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cyclacel. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cyclacel price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cyclacel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyclacel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyclacel Pharmaceuticals Inc. The current adx is 23.07.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cyclacel shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cyclacel Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyclacel Pharmaceuticals Inc. The current sar is 1.56424239.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cyclacel Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyclacel Pharmaceuticals Inc. The current rsi is 57.64. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Cyclacel Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCyclacel Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyclacel Pharmaceuticals Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclacel price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cyclacel Pharmaceuticals Inc Daily Stochastic Oscillator ChartCyclacel Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyclacel Pharmaceuticals Inc. The current cci is 90.61.

Cyclacel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCyclacel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyclacel Pharmaceuticals Inc. The current cmo is 29.66.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cyclacel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCyclacel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyclacel Pharmaceuticals Inc. The current willr is -6.02482227.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cyclacel Pharmaceuticals Inc Daily Williams %R ChartCyclacel Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyclacel Pharmaceuticals Inc. The current atr is 0.22228287.

Cyclacel Pharmaceuticals Inc Daily Average True Range (ATR) ChartCyclacel Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyclacel Pharmaceuticals Inc. The current obv is 6,351,405.

Cyclacel Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCyclacel Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyclacel Pharmaceuticals Inc. The current mfi is 69.90.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cyclacel Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCyclacel Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyclacel Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Cyclacel Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyclacel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.637
Ma 20Greater thanMa 501.968
Ma 50Greater thanMa 1002.310
Ma 100Greater thanMa 2002.618
OpenGreater thanClose1.860
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyclacel with someone you think should read this too:
  • Are you bullish or bearish on Cyclacel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyclacel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyclacel Pharmaceuticals Inc

I send you an email if I find something interesting about Cyclacel Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyclacel Pharmaceuticals Inc.

Receive notifications about Cyclacel Pharmaceuticals Inc in your mailbox!